The influenza vaccine market in Italy is expected to reach a projected revenue of US$ 277.1 million by 2030. A compound annual growth rate of 6% is expected of Italy influenza vaccine market from 2024 to 2030.
In terms of revenue, Italy accounted for 2.3% of the global influenza vaccine market in 2023.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
In Europe, Germany influenza vaccine market is projected to lead the regional market in terms of revenue in 2030.
Denmark is the fastest growing regional market in Europe and is projected to reach USD 31.6 million by 2030.
Increasing R&D investments and continuous research by scientists have boosted the demand for novel vaccines in Italy. In addition, the increasing prevalence of seasonal flu & influenza in the country and continuous strategic initiatives being implemented by regional players to provide innovative solutions are expected to support the market growth.
For instance, in April 2021, Italy’s Farm industrial identified several Italian companies ready for the bottling of vaccines, and four of those can activate bioreactors for vaccine production. The bioreactor activation can provide a better chance to boost the vaccine supply in the country.
In addition, in July 2021, Catalent announced plans for USD 100 million expansion of its plant in Italy to meet increasing demand for vaccines in the country. Thus, the abovementioned factors are expected to create robust growth opportunities for the market in coming years.
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Influenza Vaccine Market Outlook will help companies and investors design strategic landscapes.
Inactivated was the largest segment with a revenue share of 96.12% in 2023.
Horizon Databook has segmented the Italy influenza vaccine market based on inactivated, live attenuated covering the revenue growth of each sub-segment from 2018 to 2030.
Increasing R&D investments and continuous research by scientists have boosted the demand for novel vaccines in Italy. In addition, the increasing prevalence of seasonal flu & influenza in the country and continuous strategic initiatives being implemented by regional players to provide innovative solutions are expected to support the market growth.
For instance, in April 2021, Italy’s Farm industrial identified several Italian companies ready for the bottling of vaccines, and four of those can activate bioreactors for vaccine production. The bioreactor activation can provide a better chance to boost the vaccine supply in the country.
In addition, in July 2021, Catalent announced plans for USD 100 million expansion of its plant in Italy to meet increasing demand for vaccines in the country. Thus, the abovementioned factors are expected to create robust growth opportunities for the market in coming years.
Italy Influenza Vaccine Market Vaccine Type Outlook (Revenue, USD Million , 2018-2030)
Inactivated
Live Attenuated
Italy Influenza Vaccine Market Indication Outlook (Revenue, USD Million , 2018-2030)
Quadrivalent
Trivalent
Italy Influenza Vaccine Market Age Group Outlook (Revenue, USD Million , 2018-2030)
Pediatric
Adult
Italy Influenza Vaccine Market Route of Administration Outlook (Revenue, USD Million , 2018-2030)
Injection
Nasal Spray
Italy Influenza Vaccine Market Distribution Channel Outlook (Revenue, USD Million , 2018-2030)
Hospitals & Pharmacy
Government & Institutional supply
Other Distribution Channels
Reasons to subscribe to Influenza Vaccine Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Influenza Vaccine Market Outlook databook
Our clientele includes a mix of Influenza Vaccine Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Italy Influenza Vaccine Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Italy Influenza Vaccine Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.